Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

12,958 total articles

Fortuna reports production of 72,872 gold equivalent ounces in the first quarter of 2026 and provides a business update

Fortuna reports production of 72,872 gold equivalent ounces in the first quarter of 2026 and provides a business update

Fortuna Mining Corp. announced first-quarter 2026 production of 72,872 gold equivalent ounces, exceeding prior quarters and reaffirming 2026 guidance of 281,000 to 305,000 GEO. The company is progressing key growth initiatives including the Se9gue9la plant expansion and the Diamba Sud feasibility study. Additionally, it repurchased 2.2 million shar…

GEN Korean BBQ To Sell All Products at 190 Grocery Stores

GEN Korean BBQ To Sell All Products at 190 Grocery Stores

GEN Restaurant Group, Inc., owner of GEN Korean BBQ, announced the expansion of its retail product lineup to include 22 SKUs available in 190 grocery stores nationwide. The move capitalizes on the global popularity of Korean culture and customer demand, enabling fans to enjoy their favorite Korean BBQ products outside of restaurants. The product li…

Rezolve Ai Rejects Commerce.com Board’s Fantasies on Stand-alone Recovery, Sets Path for Accelerated Value Creation

Rezolve Ai Rejects Commerce.com Board’s Fantasies on Stand-alone Recovery, Sets Path for Accelerated Value Creation

Rezolve Ai PLC publicly responded to Commerce.com's Board rejection of Rezolve's proposed acquisition offer, criticizing Commerce.com's growth outlook and valuing Rezolve's 7.5x year-on-year revenue growth and contracted sales. Rezolve commits to further engagement with Commerce.com shareholders to promote a merger aimed at accelerating liquidity, …

Whitestone REIT to Be Acquired by Ares for $1.7 Billion

Whitestone REIT to Be Acquired by Ares for $1.7 Billion

Whitestone REIT announced a definitive merger agreement to be acquired by Ares Management Corporation for $19.00 per share, representing a 12.2% premium to the prior closing price and totaling approximately $1.7 billion. The deal, approved by Whitestone's Board, is expected to close in Q3 2026, and will result in Whitestone becoming a privately hel…

Equinox Gold Delivers Strong First Quarter with 197,628 Ounces of Gold Production, $990 Million of Debt Reduction and Inaugural Dividend Payment

Equinox Gold Delivers Strong First Quarter with 197,628 Ounces of Gold Production, $990 Million of Debt Reduction and Inaugural Dividend Payment

Equinox Gold Corp. delivered a robust first quarter in 2026 with gold production totaling 197,628 ounces, including strong contributions from its Canadian operations. The company successfully reduced debt by $990 million and initiated its inaugural quarterly dividend of $0.015 per share. Operational improvements at Greenstone and Valentine mines ar…

Five Star Bank announces commitment to a $10 million Low Income Housing Tax Credit Investment in the Marvel in the Mission, providing 136-units of permanent supportive housing to San Francisco residents

Five Star Bank announces commitment to a $10 million Low Income Housing Tax Credit Investment in the Marvel in the Mission, providing 136-units of permanent supportive housing to San Francisco residents

Five Star Bancorp has announced a $10 million Low Income Housing Tax Credit (LIHTC) investment in the Marvel in the Mission development, a 136-unit permanent supportive housing project in San Francisco's Mission District. This marks the bank's first such investment in the Bay Area, supporting affordable housing combined with wraparound services to …

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

Invivyd announces progress in its Phase 3 pivotal DECLARATION study of VYD2311 for COVID-19 prevention, including a sample size increase to enhance statistical power and a slight delay in expected top-line results to Q3 2026. The company also reveals discovery and rapid development plans for VMS063, a novel, potentially first- and best-in-class mon…

Occidental Announces Gulf of America Oil Discovery at Bandit

Occidental Announces Gulf of America Oil Discovery at Bandit

Occidental Petroleum Corporation reported a new oil discovery at the Bandit prospect located about 125 miles south of Louisiana in the Gulf of America. The discovery involves high-quality, full-to-base oil-bearing Miocene sands and offers potential subsea infrastructure tie-backs to existing nearby facilities. Occidental, which operates the site an…

Nkarta to Participate in Needham Virtual Healthcare Conference

Nkarta to Participate in Needham Virtual Healthcare Conference

Nkarta, Inc., a clinical-stage biopharmaceutical company specializing in engineered natural killer (NK) cell therapies for autoimmune diseases, announced its participation in the 25th Annual Needham Virtual Healthcare Conference. Company executives will discuss their investigational CAR-NK cell therapy targeting B cell-mediated autoimmune diseases …

Seres Therapeutics to Present at CARB-X Investor Day

Seres Therapeutics to Present at CARB-X Investor Day

Seres Therapeutics announced its presentation at the 2026 CARB-X Investor Day, underscoring its ongoing collaboration with CARB-X to develop novel live biotherapeutics targeting antimicrobial resistance (AMR). The company highlighted its advancement of SER-428, an oral liquid formulation intended for ICU patients at high risk of AMR infections, sup…

Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate

Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate

Kymera Therapeutics announced that Gilead Sciences has exercised its option to exclusively license KT-200, a novel oral CDK2 molecular glue degrader developed by Kymera. This triggers a $45 million milestone payment to Kymera, with Gilead advancing the program toward IND-enabling studies for a potential 2027 IND filing. KT-200 offers a targeted the…

Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

Rani Therapeutics, a clinical-stage biotherapeutics company listed on Nasdaq, announced the appointment of Dr. Sara Kenkare-Mitra as Strategic Advisor. Dr. Kenkare-Mitra brings extensive expertise in biologics development and will support the advancement of Rani's oral biologics platform, including their RaniPill technology and programs such as ora…